From its acute to recurrent forms, pericardial disease can be daunting for patients and clinicians alike. A world expert brings us up to date on diagnostics, stepwise therapy and emerging advanced medications.
The veteran cardiologist reflects on the meeting’s biggest developments: the new cholesterol guideline, the VITAL trial of vitamin D, the REDUCE-IT controversy and a strikingly potent therapy for lowering Lp(a).
A veteran physician researcher shares tips on getting started in clinical trials, obtaining funding, following regulatory standards and making your research efforts a success.
We’ve launched a weekly provider-targeted podcast where cardiovascular physicians explore timely research and clinical developments shaping their practice.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Dr. Steven Nissen shares what you need to know from five impactful trials — ATTR-ACT, ARRIVE, ASCEND, AIMS and MITRA-FR — presented at the European Society of Cardiology Congress in Munich.
Don’t equate flaws in the PREDIMED trial with flaws in the diet it studied, Dr. Steve Nissen argues, especially when the effect on the results proved so modest.
Adding aspirin to chronic NSAID therapy slightly modifies celecoxib’s safely profile relative to that of two nonselective NSAIDs, but not enough to alter conclusions of the primary PRECISION trial report.
A genotype found to be associated with reduced cardiovascular events in a study of dalcetrapib wasn’t associated with benefit in a trial of fellow CETP inhibitor evacetrapib.
A pending USPSTF recommendation on nontraditional cardiac risk factors for asymptomatic adults gets it right for two of three factors addressed, contends Dr. Steve Nissen.
Dr. Steven Nissen draws lessons for healthcare providers from Cleveland Clinic’s latest national survey of adults’ heart health knowledge and practices.